- Home
- PETZ vs BOLT Comparison
PETZ vs BOLT Comparison
Compare PETZ & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | BOLT |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | China | United States |
| Employees | 12 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.5M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PETZ | BOLT |
|---|---|---|
| Price | $1.13 | $4.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 8.1K | ★ 24.9K |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.81 | $3.75 |
| 52 Week High | $1.83 | $7.20 |
Technical Indicators
Market Signals| Indicator | PETZ | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 55.78 |
| Support Level | $1.11 | $4.39 |
| Resistance Level | $1.23 | $5.05 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 13.01 | 100.00 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.